PERU
On March 29, the Health Committee approved the opinion that proposes the law for the prevention of cancer in women and the strengthening of specialized oncological care. The initiative seeks to have an impact on the prevention, control and specialized care of breast and cervical cancer. The initiative is ready to be analyzed by the plenary, which is expected to happen in the short term. On the other hand, the Ministry of Health established the procedure for the report on the temporary or definitive discontinuation and reactivation of the manufacture or importation of medicines, by the holders of sanitary registration or sanitary registration certificate.
- Opinion proposing the law for the prevention of cancer in women
The proposal brings together bills 1074 and 1430, whose objective is to guarantee the full exercise of the fundamental right to health and access to health services in accordance with the Constitution and international instruments in force. For her part, legislator Kira Alcarraz (Somos Perú) explained that the application of the law is nationwide and it is expected to include leave rights (one day a year) for early detection exams for breast and cervical cancer. The proposal also states that the Ministry of Health must establish a procedure for the priority care of patients diagnosed with cancer.
- Procedure for reporting on discontinuation of manufacture or importation
The directive states that laboratories and drugstores are obliged to report to the National Pharmaceutical Products Authority (ANM in Spanish) the temporary or definitive discontinuation of a drug, as well as its reactivation. The report will be submitted through the ANM’s web application called “Registration of temporary discontinuation“. The report must include the general data of the laboratory (company name, address and Single Taxpayer Registry), as well as the data of the sanitary registration or the sanitary registration certificate of the medicine (name of the product, pharmaceutical form, concentration, route of administration and Active Pharmaceutical Ingredient). The regulation is already in force.